Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, ...

A new report sheds more light on a potential mobile network offering from SpaceX, though it's not clear how it would work.